United States Patent 6,020,358: Claim Scope, Apremilast Coverage, Expiration and Patent Landscape

U.S. Patent No. 6,020,358 covers a broad genus of chiral aryl-substituted sulfones, including compounds that inhibit phosphodiesterase IV and reduce tumor necrosis factor-alpha, or TNF-alpha. The patent is historically important because its claim structure reaches the apremilast chemical family, although the patent itself is no longer an enforceable barrier to generic entry. Apremilast is a small-molecule drug, so biosimilar analysis does not apply. Current commercial risk depends on later patents covering apremilast polymorphs, formulations, dosing regimens, and other product-specific subject matter, not on Patent 6,020,358 alone.

What drug does U.S. Patent 6,020,358 cover?

The patent covers sulfone compounds built around a chiral benzylic carbon attached to:

An aryl group, including substituted phenyl and naphthyl systems.
A sulfone-containing side chain.
An isoindolinone, isoindoline-1,3-dione, or related cyclic imide structure.

The compound most closely associated with the patent family is apremilast, whose chemical name is:

(S)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetamidoisoindoline-1,3-dione.

Apremilast is marketed by Amgen under the brand Otezla. It is approved for psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. The FDA classifies apremilast as a phosphodiesterase-4 inhibitor rather than as a biologic product. [2]

The supplied claim text appears to contain transcription or OCR errors, including "ethyoxy" and "isondoline." The operative chemical scope is determined by the issued patent drawings, specification, prosecution history, and corrected claim text, not by those typographical artifacts.

How broad is independent claim 1?

Claim 1 is a Markush composition-of-matter claim. It does not protect one named compound only. It claims a selected class of sulfones and their acid-addition salts.

The principal structural limitations are:

Claim element	Scope
Core class	A sulfone
Stereochemistry	The carbon marked "*" is a center of chirality
Linker variable Y	Carbonyl, methylene, or methylene-carbonyl
First aryl ring	Substituted phenyl or fused naphthylidene
R1-R4	Hydrogen, halogen, C1-C4 alkyl, C1-C4 alkoxy, nitro, cyano, hydroxy, or amino-derived substituents
R5-R6	Hydrogen, C1-C4 alkyl, C1-C4 alkoxy, cyano, or cycloalkoxy
R7	Hydroxy, C1-C8 alkyl, phenyl, benzyl, or amino
Sulfone substituent	Methyl, other alkyl, phenyl, or substituted amino-sulfonyl groups
Salt coverage	Acid-addition salts of protonatable nitrogen-containing compounds

The claim is broad in substituent selection but narrow in scaffold architecture. A compound must fall within both categories:

The claimed aryl-substituted chiral sulfone framework.
The claimed cyclic amide or imide framework represented by the patent's chemical formula.

A structurally unrelated PDE4 inhibitor would not infringe merely because it inhibits PDE4. Patent infringement turns on the claimed molecular structure, not on pharmacological activity alone.

What stereochemical limitation applies?

Claim 1 expressly identifies the "*" carbon as a center of chirality. The claim therefore raises a stereochemical construction issue. Depending on the specification and prosecution history, the claim may cover:

One enantiomer;
Both optical isomers where the claim language does not assign an absolute configuration;
Racemic mixtures containing the claimed structural relationship;
Certain salts of the claimed stereochemical form.

The claim text supplied does not identify the absolute configuration as R or S. A definitive infringement opinion would require the patent's structural figure, specification, and file history. The broadest commercial relevance is that apremilast is the S-enantiomer, and the patent family helped establish protection for this chiral sulfone class.

What do claims 2 through 15 add?

Claims 2 through 15 are dependent claims that narrow the substitution pattern.

Claim	Limitation
2	Y is carbonyl
3	Y is methylene
4	Restricted ring substituents, including hydrogen, halogen, methyl, ethyl, methoxy, ethoxy, nitro, cyano, hydroxy, and amino groups
5	One ring substituent is amino
6	One ring substituent is acetamido
7	One ring substituent is methyl or ethyl
8	One ring substituent is fluoro
9	One ring substituent is dimethylamino
10	Narrow R5 and R6 alkyl, alkoxy, or cycloalkoxy groups
11	Both R5 and R6 are alkoxy or cycloalkoxy substituents
12	R5 is methoxy and R6 is ethoxy
13	R7 is hydroxy, alkyl, phenyl, benzyl, or a restricted amino group
14	R7 is methyl
15	R7 is dimethylamino or a closely related amino substituent

The dependent claims create multiple fallback positions. For apremilast-type molecules, the most relevant limitations are:

The 3-ethoxy-4-methoxyphenyl substitution pattern under claims 10 through 12.
The acetamido substitution under claim 6.
The methylsulfonyl side chain under claim 1 and the named compounds in claim 16.
The cyclic imide structure.
The required chiral carbon.

Claim 12 is especially relevant to apremilast-like compounds because it expressly narrows the aryl substituents to methoxy and ethoxy groups in the claimed positions.

Does claim 16 specifically cover apremilast?

Claim 16 lists specific compounds, but the supplied version does not clearly recite the standard apremilast name. It lists compounds with:

A 3-ethoxy-4-methoxyphenyl group;
A 2-methylsulfonylethyl side chain;
Isoindoline-1,3-dione or related imide cores;
Nitro, amino, methyl, acetamido, dimethylamino, methoxy, or fused-ring substitutions.

The omission of the conventional 4-acetamido apremilast structure from the supplied list may reflect a transcription error, a claim-text extraction error, or a distinction between a named compound and the broader genus of claim 1. Even if claim 16 did not expressly name apremilast, claim 1 and claim 6 could still reach it if the molecule satisfies every limitation.

A named-compound claim is generally narrower than the corresponding genus claim. If a product is not literally one of the compounds listed in claim 16, infringement may still exist under claim 1 or another dependent claim.

What methods of use does Patent 6,020,358 protect?

Claims 17 and 18 are method-of-use claims.

Claim 17: TNF-alpha reduction

Claim 17 covers administering an effective amount of a claimed compound to a mammal to reduce undesirable TNF-alpha levels.

This language potentially reaches treatment of diseases in which TNF-alpha is implicated, but the enforceable scope depends on claim construction and the patent's written description. The claim does not identify a particular disease, dose, route, patient subgroup, or treatment duration.

Claim 18: PDE IV inhibition

Claim 18 covers administering an effective amount of a claimed compound to a mammal to inhibit PDE IV.

This is a functional method claim. It requires:

Administration to a mammal.
An effective amount.
A compound within claim 1.
Inhibition of PDE IV.

A generic manufacturer selling the compound for an approved indication could face method-of-use issues only if a live patent covers the indication and the generic labeling induces the patented use. Patent 6,020,358 itself is no longer an active enforcement obstacle.

Claim 19: Pharmaceutical composition

Claim 19 covers a composition containing:

A quantity of a claim 1 compound sufficient to reduce TNF-alpha in a mammal; and
A carrier.

The composition claim is broad. It does not require a specific tablet, capsule, excipient, release profile, particle size, dosage strength, or manufacturing process. Later formulation patents can therefore cover commercial products even when the original composition claim has expired.

What formulation patents are separate from Patent 6,020,358?

Patent 6,020,358 does not appear, from the supplied claims, to contain narrow commercial formulation limitations. It does not specifically require:

A particular crystalline form;
A defined polymorph;
A specific particle-size distribution;
A controlled-release matrix;
A particular tablet coating;
A defined dissolution profile;
A fixed-dose combination;
A specific excipient system.

Those subjects are commonly addressed in later patent families. For apremilast, the relevant later landscape has included product-specific composition, polymorph, formulation, and therapeutic-use patents. A generic applicant would need to conduct a separate Orange Book and worldwide family review for those later rights.

When did U.S. Patent 6,020,358 lose exclusivity?

Patent 6,020,358 was issued on February 1, 2000. Its term was governed by the patent's effective filing and priority dates, together with any applicable patent-term adjustment or terminal disclaimer. Because the patent originated from the 1990s, its statutory term ended years before the current period.

The patent should be treated as expired and incapable of independently blocking a generic launch in the United States. The precise expiration date should be taken from the USPTO patent record and the patent's continuity data rather than inferred from the issue date. [1]

The practical conclusion is unchanged: Patent 6,020,358 is a historical composition and method patent, not a currently enforceable U.S. exclusion right.

What is the Orange Book status of Patent 6,020,358?

Patent 6,020,358 should not be treated as a current Orange Book barrier to Otezla generic entry. The FDA Orange Book lists patents submitted for approved drug products and identifies patent expiration and exclusivity information. Expired patents may remain visible in historical records, but they do not create a current right to exclude generic marketing. [3]

The key distinction is:

Issue	Patent 6,020,358
Composition patent	Yes
Method-of-use claims	Yes
Pharmaceutical composition claim	Yes
Current enforceable U.S. term	No
Current standalone generic barrier	No
Biosimilar relevance	None
Potential historical relevance	High
Need to review later patents	Yes

Are Paragraph IV challenges relevant to this patent?

A Paragraph IV certification is relevant only to a listed patent that remains enforceable or otherwise affects the applicant's proposed approval strategy. An ANDA applicant would not normally base a current Paragraph IV challenge on an expired patent because the patent cannot lawfully prevent approval or commercial entry after expiration.

For apremilast, Paragraph IV risk is directed principally at later unexpired patents listed for the relevant NDA. The key issues include:

Whether the generic applicant certifies that later patents are invalid, unenforceable, or not infringed;
Whether the NDA holder files a timely infringement action;
Whether a 30-month stay applies;
Whether the applicant uses a section viii statement to omit a patented method of use;
Whether the proposed label induces infringement.

Patent 6,020,358 may appear in historical prosecution or litigation records, but it should not be analyzed as the principal current Paragraph IV target.

Which companies are challenging apremilast exclusivity?

Apremilast is a small molecule, so the competitive field consists of ANDA filers rather than biosimilar sponsors. Publicly reported generic activity has involved manufacturers seeking approval for apremilast tablets or equivalent dosage forms. The commercial analysis must distinguish:

A patent challenge to the active ingredient.
A challenge to a polymorph or crystalline form.
A challenge to a formulation.
A challenge to a method-of-use patent.
A settlement that permits an agreed future entry date.

The identity of current ANDA filers, litigation defendants, and settlement terms changes as cases are filed, transferred, dismissed, or resolved. Those facts should be verified against the FDA Orange Book, FDA litigation records, PACER, and district-court dockets. Patent 6,020,358 itself does not create a current litigation risk.

How strong is the patent estate associated with this compound?

Patent 6,020,358 has historical breadth but no current blocking strength.

Strength factor	Assessment
Chemical genus	Broad
Stereochemical limitation	Material claim-construction issue
Specific apremilast coverage	Likely through the genus and acetamido-dependent claims
Method claims	Broad functional language
Formulation specificity	Limited in the supplied claims
Current enforceability	None after expiration
Design-around potential during term	Potentially meaningful through scaffold, stereochemistry, or substituent changes
Current commercial value	Prior-art and historical patent-family significance

During its term, the patent could have supported substantial leverage because composition claims generally provide stronger protection than method claims. After expiration, its principal value is as prior art against later applications and as evidence of the technical and legal history of the compound class.

What generic launch scenarios exist for apremilast?

The most relevant launch scenarios are:

Launch after all listed patents expire

This is the lowest litigation-risk path, although it delays market entry.

Paragraph IV launch against later patents

An applicant may challenge later Orange Book-listed patents and seek approval before their expiration dates. The outcome depends on claim validity, infringement, prosecution-history estoppel, and the scope of any settlement.

Section viii carve-out

If the remaining patents cover only a method of use, an applicant may attempt to omit that indication from its labeling. This strategy is less useful where the patented use is inseparable from the product's principal approved indication.

At-risk launch

A generic may launch before final resolution after receiving approval or after prevailing in litigation. This creates potential damages exposure if the patent holder later prevails.

Patent 6,020,358 does not materially alter these scenarios because its term has ended.

What geographic coverage does the patent provide?

U.S. Patent 6,020,358 provides rights only in the United States. It does not establish protection in Europe, Japan, Canada, China, India, or other jurisdictions.

The international landscape must be reconstructed from:

The priority chain;
PCT applications;
National-phase filings;
Continuation and divisional applications;
Patent-term adjustments and supplementary protection certificates;
Country-specific opposition and invalidity outcomes.

A U.S. expiration finding cannot be exported to other countries. Conversely, foreign rights cannot revive an expired U.S. patent.

What manufacturing and intellectual-property barriers remain?

The expired patent does not block manufacture of apremilast in the United States. Remaining barriers may arise from:

Later patents on polymorphs or solid-state forms;
Crystallization and purification processes;
Particle engineering;
Tablet formulation;
Manufacturing scale-up;
Stability specifications;
Analytical methods;
Regulatory exclusivity;
Trade secrets and process know-how;
Regulatory requirements for demonstrating pharmaceutical equivalence.

An API supplier may avoid a formulation patent while still infringing an API or process patent in a particular jurisdiction. A finished-dose manufacturer may avoid an API patent but infringe a tablet or method-of-use patent through its label.

Key Takeaways

U.S. Patent 6,020,358 claims a broad genus of chiral aryl-substituted sulfones.
The claim architecture reaches the apremilast chemical family through the core genus and acetamido-dependent limitations.
Claims 17 and 18 cover TNF-alpha reduction and PDE IV inhibition; claim 19 covers a broad pharmaceutical composition.
The supplied claim text contains apparent transcription errors, especially in claim 16.
The patent is expired and is not a current standalone U.S. barrier to generic apremilast entry.
Apremilast is a small molecule, so biosimilar analysis is irrelevant.
Current exclusivity analysis must focus on later Orange Book-listed patents, formulation rights, polymorphs, methods of use, and any generic litigation or settlement agreements.
Patent 6,020,358 has historical and prior-art importance but no present exclusionary strength.

FAQs

Does U.S. Patent 6,020,358 claim apremilast by name?

The supplied claims do not clearly recite the standard apremilast name in claim 16, but the broader genus and dependent acetamido claims can reach the apremilast structure if all structural limitations are satisfied.

Is apremilast a biologic subject to biosimilar competition?

No. Apremilast is an orally administered small-molecule PDE4 inhibitor regulated through the drug approval pathway. Competitors pursue ANDA approval, not biosimilar approval.

Can an expired composition patent still affect a generic application?

Yes, as prior art and as part of patent-history analysis. It cannot, however, independently prevent commercial marketing after expiration.

Does claim 19 cover every apremilast tablet?

No. Claim 19 is broad but requires a claimed compound and a carrier. Later patents may impose narrower limitations involving crystalline form, excipients, dosage strength, release properties, or manufacturing steps.

Is a Paragraph IV challenge to Patent 6,020,358 still commercially meaningful?

No. Because the patent has expired, a current Paragraph IV strategy would ordinarily focus on later unexpired patents listed for the relevant apremilast product.

References

United States Patent and Trademark Office. (2000). U.S. Patent No. 6,020,358, Sulfone compounds and methods of use thereof.
U.S. Food and Drug Administration. (2024). Otezla (apremilast) prescribing information.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
35 U.S.C. § 154. Patent term.
21 U.S.C. § 355(j). Abbreviated new drug applications and patent certifications.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	350033	⤷ Start Trial
Austria	471718	⤷ Start Trial
Australia	1447200	⤷ Start Trial
Australia	2003203681	⤷ Start Trial
Australia	756308	⤷ Start Trial
Brazil	9915201	⤷ Start Trial
Canada	2348993	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,020,358

Summary for Patent: 6,020,358